Oruka Therapeutics, Inc..
ORKA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Oruka Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of autoimmune diseases and cancer. The company's research and development efforts are centered on identifying and developing innovative drug candidates that target sp...Show More
Better Health for All
0
No evidence available to assess Oruka Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Oruka Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantifiable data points were found in the provided articles to assess Oruka Therapeutics, Inc. against the 'Fair Pay & Worker Respect' ethical value.
1
The articles primarily contain financial information, stock-related details, and general company administrative data, but lack metrics such as living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage percentages.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found across the provided articles to assess Oruka Therapeutics, Inc. against any of the 'Fair Trade & Ethical Sourcing' KPIs. The articles either explicitly stated a lack of relevant information, were inaccessible (404 errors), or contained only general policy statements regarding ethical conduct and fair dealing. These qualitative statements, such as those in the Code of Business Conduct and Ethics, do not provide the quantitative data (e.g., percentages, frequencies, incident counts, or remediation times) required by the rubric's KPIs for scoring.
1
Honest & Fair Business
-30
Oruka Therapeutics has a formal Whistleblower and Complaint Policy, including a confidential and anonymous hotline managed by a third party, Whistleblower Services.
1
The company pledges no retaliation for good-faith reports, and complaints involving the General Counsel or conflicts of interest are directed to the Audit Committee or outside counsel.
2
A 14 to 16-digit code is provided to track the status of messages submitted through the hotline.
3
The company's audited financial statement as of February 6, 2024, was retroactively adjusted to reflect a reverse stock split and exchange ratio, constituting one restatement in the past three years.
4
The company's Code of Business Conduct and Ethics, dated August 29, 2024, states compliance with the Foreign Corrupt Practices Act (FCPA) and prohibits offering anything of value to inappropriately influence clinical studies or government officials.
5
However, there is no evidence of training frequency or effectiveness metrics for this policy. The financial statement was audited by PricewaterhouseCoopers LLP.
6
The whistleblower hotline is managed by a third party.
7
Kind to Animals
0
No specific, concrete evidence was found in the provided articles to assess Oruka Therapeutics, Inc. against any of the 'Kind to Animals' KPIs. While Article 1 mentions the company's preclinical data was derived from non-human primates,
1
it does not provide quantitative details such as the number of animals used, the percentage of alternative methods employed, or specific policies regarding animal testing. Article 0 discusses the FDA's general roadmap for reducing animal testing and industry benchmarks,
2
but this information is not specific to Oruka Therapeutics, Inc. Article 2 is a general review of alternative testing methods,
3
and Article 3 was inaccessible.
4
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess Oruka Therapeutics, Inc. against any of the Key Performance Indicators for the 'No War, No Weapons' ethical value. The articles either contained no relevant data, were job postings, or were legal terms and conditions documents that did not provide quantifiable actions or policies related to arms, defense, or peacebuilding activities. Several attempts to access SEC filings were throttled, preventing data retrieval.
1
Planet-Friendly Business
0
No specific sustainability data or environmental performance metrics for Oruka Therapeutics, Inc. were available in the provided articles.
1
Both sources indicated that sustainability data was either unavailable or could not be extracted.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Oruka Therapeutics, Inc.'s engagement with local or indigenous communities, cultural preservation efforts, local employment, procurement, or any related social responsibility initiatives relevant to the 'Respect for Cultures & Communities' value.
1
The articles primarily focus on drug development, clinical trials, and financial filings, and explicitly state a lack of data for all relevant KPIs.
2
Safe & Smart Tech
0
No evidence available to assess Oruka Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Oruka Therapeutics, Inc. on Zero Waste & Sustainable Products.